Glythera, a biotechnology company based in Newcastle-Upon-Tyne in the UK, has appointed Nigel Burns as Non-Executive Director and Ian Evetts as Commercial Director.
The company specialises in the development of bio-therapeutics, including antibody drug conjugates, through the application of its proprietary linker and stable glycan technologies PermaLink and PermaCarb, and the addition of the two men coincides with the company’s plan to explore new opportunities.
Burns brings more than 25 years' experience in the biopharmaceuticals and biotechnology industry to Glythera. He has held a series of leadership roles including Senior Vice President of Cambridge Antibody Technology, Non-Executive Director of Navion, Chairman of Cell Medica, Director and Founder of Nascient and most recently, CEO and Founder of SweetSpot Therapeutics. As Non-Executive Director, Burns will support the development of Glythera’s technology and future business strategies.
Ian Evetts
Evetts joins Glythera with more than 20 years' experience in the pharmaceutical industry. He has a track record of senior strategic and operational roles including Managing Director at Atebion BDS, Strategic Advisor at Bionure, and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.
